Allogeneic CAR T Cells Targeting DLL3 Are Efficacious and Safe in Preclinical Models of Small Cell Lung Cancer

• Published in: Clinical cancer research 2023-03, Vol.29 (5), p.971-985
• Main Authors: Zhang, Yi, Tacheva-Grigorova, Silvia K, Sutton, Janette, Melton, Zea, Mak, Yvonne S L, Lay, Cecilia, Smith, Bryan A, Sai, Tao, Van Blarcom, Thomas, Sasu, Barbra J, Panowski, Siler H
• Format: Article
• Language: English
• Subjects: Animals; Hematopoietic Stem Cell Transplantation; Ligands; Lung Neoplasms - drug therapy; Male; Mice; Small Cell Lung Carcinoma - genetics; T-Lymphocytes - metabolism
• ISSN: 1078-0432; 1557-3265
• DOI: 10.1158/1078-0432.CCR-22-2293

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options. Delta-like ligand 3 (DLL3) is highly expressed on SCLC and several other types of neuroendocrine cancers, with limited normal tissue RNA expression in brain, pituitary, and testis, making it a promising CAR T-cell target for SCLC and other solid tumor indications. A large panel of anti-DLL3 scFv-based CARs were characterized for both in vitro and in vivo activity. To understand the potential for pituitary and brain toxicity, subcutaneous or intracranial tumors expressing DLL3 were implanted in mice and treated with mouse cross-reactive DLL3 CAR T cells. A subset of CARs demonstrated high sensitivity for targets with low DLL3 density and long-term killing potential in vitro. Infusion of DLL3 CAR T cells led to robust antitumor efficacy, including complete responses, in subcutaneous and systemic SCLC in vivo models. CAR T-cell infiltration into intermediate and posterior pituitary was detected, but no tissue damage in brain or pituitary was observed, and the hormone-secretion function of the pituitary was not ablated. In summary, the preclinical efficacy and safety data presented here support further evaluation of DLL3 CAR T cells as potential clinical candidates for the treatment of SCLC.